By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Over the last 12 months, four Pasithea Therapeutics Corp. corporate insiders bought shares with their own money, about $203,000 in total, and none of them sold.
Biggest single buyer: STEINMAN LAWRENCE, Director, with roughly $100,000. Notably, at least one C-suite executive was among the buyers.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters. 25 investment managers listed KTTA in their latest 13F filings (Q2 2026); more funds bought than sold.
Are insiders buying or selling KTTA stock?
In the last 12 months Pasithea Therapeutics Corp. insiders made open-market purchases worth about $203,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in KTTA?
The most recent open-market insider trade in KTTA was filed on 2026-06-22.
How many institutions own KTTA?
25 investment managers reported holding KTTA in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded KTTA?
No congressional trades in KTTA were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).